Breast Cancer | Topics

 
Subcutaneous Treatment of Early-Stage HER2+ Breast Cancer During the COVID-19 Pandemic
May 11, 2022

Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.

Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injections for Early-Stage HER2+ Breast Cancer
May 11, 2022

An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.

Leptomeningeal Metastases in HER2+ Breast Cancer
May 09, 2022

A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.

Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases
May 09, 2022

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Frontline Treatment Options for Early-Stage HER2+ Breast Cancer
May 06, 2022

Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.

Goals of Care for Patients with Early-Stage versus Advanced or Metastatic HER2+ Breast Cancer
May 06, 2022

Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.

First-Line Ribociclib Combo Yields Significant OS Benefit Vs Fulvestrant in Postmenopausal HR+, HER2- Advanced Breast Cancer
May 05, 2022

Updated findings from the phase 3 MONALESSA-3 trial identified a significant overall survival benefit among postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who were treated with ribociclib and fulvestrant vs matched placebo.

Clinical Case Presentation: A 53-Year-Old Woman with Metastatic ER/PR+ HER2+ Breast Cancer and Brain Metastases
May 02, 2022

Dr Stefania Maraka presents the case of a 53-year-old woman with de novo metastatic mutated ER/PR+ HER2+ breast cancer and brain metastases.

Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib
May 02, 2022

Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.

Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection
April 25, 2022

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.